Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 26 - 29
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052111s26
Publié en ligne 15 novembre 2005
  1. Hornbostel H. Das angiokeratoma corporis diffusum universale mit kardio-vaso-renalem symptomenkomplex als neuartige thesaurismoseform. Helvetica Medica Acta 1952; 19 : 388–96.
  2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease : clinical manifestations and impact of the disease in a cohort of 98 hemizygous males.J Med Genet 2001; 38 : 750–60.
  3. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24 : 715–24.
  4. Wilcox W, Banikazemi M, Guffon N, et al. Long-term safety and efficacity of enzyme replacement therapy Fabry disease. Am J Hum Genet 2004; 75 : 65–74.
  5. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 2004; 34 : 236–42.
  6. Valeriani M, Mariotti P, Le Pera D, et al. Functional assessment of A delta and C fibers in patients with Fabry’s disease. Muscle Nerve 2004; 30 : 708–13.
  7. Beck M, Whybra C, Wendrick K, et al. Fabry disease in children and adolescent. Contrib Nephrol 2001; 136 : 251–5.
  8. Filling-Katz MR, Merrick HF, Fink JK, et al. Carbamazepine in Fabry’s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 1989; 39 : 598–600.
  9. Hilz MJ, Brys M, Marthol H, et al. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004; 62 : 1066–72.
  10. Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve 2002; 26 : 622–9.
  11. Gomes I, Nora DB, Becker J, et al. Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease. J Neurol Sci 2003; 214 : 21–5.
  12. Lacomis D, Roeske-Anderson L, Mathie L. Neuropathy and Fabry’s disease. Muscle Nerve 2005; 31 : 102–7.
  13. Hozumi I, Nishizawa M, Ariga T, et al. Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry’s disease. J Neurol Sci 1989; 90 : 273–80.
  14. De Veber GA, Schwarting GA, et al. Fabry disease : immunocytochemical characterization of neuronal involvement. Ann Neurol 1992; 31 : 409–15.
  15. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996; 40 : 8–17.
  16. Germain DP, Avan P, Chassaing A, et al. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002; 3 : 10.
  17. Cable WJ, Kolodny EH, Adams RD. Fabry disease : impaired autonomic function. Neurology 1982; 32 : 498–502.
  18. Giacomini PS, Shannon PT, Clarke JT, et al. Fabry’s disease presenting as stroke in a young female. Can J Neurol Sci 2004; 31 : 112–4.
  19. Moore DF, Altarescu G, Braker WC, et al. White matter lesion in Fabry disease occurs in prior selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62 : 231–40.
  20. Moore DF, Scott LTC, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Reversal after enzyme replacement. Circulation 2001; 104 : 1506–12.
  21. Boutouyrie P, Laurent S, Laloux B, et al. Non- invasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet 2001; 38 : 629–31.
  22. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000; 47 : 229–33.
  23. Hilz MJ, Kolodony EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004; 251 : 564–70.
  24. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50 : 1746–9.
  25. Moore DF, Ye F, Schiffmann R, et al. Increased signals intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 2003; 62 : 231–40.
  26. Takanashi JI, Barkovich J, Dillon WP, et al. T1 hyperintensity in the pulvinar : key imaging feazture for diagnosis of Fabry disease. Am J Neuroradiol 2003; 24 : 916–21.
  27. Tedeschi G, Bonavita S, Banerjee TK, et al. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999; 52 : 1663–7.
  28. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33 : 525–31.
  29. Germain DP. La maladie de Fabry en 2004 : l’avènement de la thérapeutique. Rev Prat 2003; 53 : 2215–20.
  30. Demuth K, Germain DP. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr 2002; 91 : 57–61.
  31. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase replacement therapy in Fabry’s disease. N Engl J Med 2001; 345 : 9–16.
  32. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62 : 1933–46.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.